Literature DB >> 28578786

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era.

Joon H Uhm1, Alyx B Porter2.   

Abstract

The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers' understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28578786     DOI: 10.1016/j.mayocp.2017.01.010

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

1.  Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells.

Authors:  Xiao-Xiao He; Shuang Du; Shi-Qian Gao; Jing-Ying Chen; Ran-Juan Cao; Zhen-Kai Xing; Alia Rizvi Syeda Kazim; Hua-Li Yu; Qing-Chuan Zheng; Xiao-Juan Zhu
Journal:  J Cell Mol Med       Date:  2018-03-24       Impact factor: 5.310

Review 2.  MicroRNA in Glioblastoma: An Overview.

Authors:  Barbara Banelli; Alessandra Forlani; Giorgio Allemanni; Anna Morabito; Maria Pia Pistillo; Massimo Romani
Journal:  Int J Genomics       Date:  2017-11-06       Impact factor: 2.326

3.  Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade.

Authors:  Radek Lakomy; Tomas Kazda; Iveta Selingerova; Alexandr Poprach; Petr Pospisil; Renata Belanova; Pavel Fadrus; Vaclav Vybihal; Martin Smrcka; Radim Jancalek; Ludmila Hynkova; Katarina Muckova; Michal Hendrych; Jiri Sana; Ondrej Slaby; Pavel Slampa
Journal:  Front Oncol       Date:  2020-07-03       Impact factor: 6.244

4.  Sinoporphyrin sodium is a promising sensitizer for photodynamic and sonodynamic therapy in glioma.

Authors:  Ya-Wen An; Han-Qing Liu; Zi-Qian Zhou; Jian-Chun Wang; Guang-Yu Jiang; Zhi-Wen Li; Feng Wang; Hong-Tao Jin
Journal:  Oncol Rep       Date:  2020-07-17       Impact factor: 3.906

5.  Selected by gene co-expression network and molecular docking analyses, ENMD-2076 is highly effective in glioblastoma-bearing rats.

Authors:  Sheng Zhong; Yang Bai; Bo Wu; Junliang Ge; Shanshan Jiang; Weihang Li; Xinhui Wang; Junan Ren; Haiyang Xu; Yong Chen; Gang Zhao
Journal:  Aging (Albany NY)       Date:  2019-11-09       Impact factor: 5.682

6.  The Effectiveness of Dichloroacetate on Human Glioblastoma Xenograft Growth Depends on Na+ and Mg2+ Cations.

Authors:  Donatas Stakišaitis; Eligija Damanskienė; Rūta Curkūnavičiūtė; Milda Juknevičienė; Marta Maria Alonso; Angelija Valančiūtė; Saulius Ročka; Ingrida Balnytė
Journal:  Dose Response       Date:  2021-02-27       Impact factor: 2.658

7.  Tat-NTS Suppresses the Proliferation, Migration and Invasion of Glioblastoma Cells by Inhibiting Annexin-A1 Nuclear Translocation.

Authors:  Zhenzhao Luo; Li Liu; Xing Li; Weiqun Chen; Zhongxin Lu
Journal:  Cell Mol Neurobiol       Date:  2021-08-03       Impact factor: 4.231

Review 8.  Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?

Authors:  Tomas Kazda; Adam Dziacky; Petr Burkon; Petr Pospisil; Marek Slavik; Zdenek Rehak; Radim Jancalek; Pavel Slampa; Ondrej Slaby; Radek Lakomy
Journal:  Radiol Oncol       Date:  2018-06-06       Impact factor: 4.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.